Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
出版年份 2021 全文链接
标题
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
作者
关键词
-
出版物
ONCOGENE
Volume 40, Issue 37, Pages 5590-5599
出版商
Springer Science and Business Media LLC
发表日期
2021-07-24
DOI
10.1038/s41388-021-01911-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- C-Jun drives melanoma progression in PTEN wild type melanoma cells
- (2019) Melanie Kappelmann-Fenzl et al. Cell Death & Disease
- AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma
- (2018) Qiang Zuo et al. ONCOGENE
- In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
- (2018) Jessica L.F. Teh et al. Cancer Discovery
- A Preexisting Rare PIK3CA E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling
- (2018) Gabriele Romano et al. Cancer Discovery
- MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas
- (2017) Hezhe Lu et al. NATURE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma
- (2017) Clemens Krepler et al. Cell Reports
- Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
- (2016) Sarah J. Welsh et al. EUROPEAN JOURNAL OF CANCER
- Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
- (2016) Patricia Mucci LoRusso JOURNAL OF CLINICAL ONCOLOGY
- mTORC1 and mTORC2 in cancer and the tumor microenvironment
- (2016) L C Kim et al. ONCOGENE
- BEZ235: When Promising Science Meets Clinical Reality
- (2016) G. Pongas et al. ONCOLOGIST
- A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
- (2016) Maria I. Carlo et al. ONCOLOGIST
- BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
- (2015) Zhan Yao et al. CANCER CELL
- Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
- (2015) Gatien Moriceau et al. CANCER CELL
- Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
- (2015) C. Krepler et al. CLINICAL CANCER RESEARCH
- Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
- (2015) Lawrence N. Kwong et al. JOURNAL OF CLINICAL INVESTIGATION
- PTEN regulates IGF-1R-mediated therapy resistance in melanoma
- (2015) Jun Wang et al. Pigment Cell & Melanoma Research
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade
- (2015) Ilaria Penna et al. Oncotarget
- Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
- (2015) Melanie Sweetlove et al. Frontiers in Oncology
- Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
- (2015) Ryan B. Corcoran et al. Oncotarget
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1 and Oxidative Phosphorylation in Melanoma
- (2014) Y. N. V. Gopal et al. CANCER RESEARCH
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
- (2014) H. Rizos et al. CLINICAL CANCER RESEARCH
- Systemic treatment for BRAF-mutant melanoma: where do we go next?
- (2014) Alexander M Menzies et al. LANCET ONCOLOGY
- BRAF V600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation
- (2014) Jillian M. Silva et al. MOLECULAR CANCER RESEARCH
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
- (2014) Lise Boussemart et al. NATURE
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
- (2014) Georgina V. Long et al. Nature Communications
- A pan-cancer proteomic perspective on The Cancer Genome Atlas
- (2014) Rehan Akbani et al. Nature Communications
- Targeting PI3K/Akt/mTOR Signaling in Cancer
- (2014) Camillo Porta et al. Frontiers in Oncology
- Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma
- (2013) Xiaoqi Xie et al. PLoS One
- TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma
- (2013) R. B. Corcoran et al. Science Translational Medicine
- A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
- (2013) H. Shi et al. Cancer Discovery
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
- (2013) Jessie Villanueva et al. Cell Reports
- Roles of the mammalian target of rapamycin, mTOR, in controlling ribosome biogenesis and protein synthesis: Figure 1
- (2012) Valentina Iadevaia et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- The mTOR Signalling Pathway in Human Cancer
- (2012) Helena Pópulo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
- (2012) J. G. Greger et al. MOLECULAR CANCER THERAPEUTICS
- Combinatorial Treatments That Overcome PDGFR -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
- (2011) H. Shi et al. CANCER RESEARCH
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition
- (2011) W. Deng et al. Pigment Cell & Melanoma Research
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
- (2011) Mohammad Atefi et al. PLoS One
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
- (2010) Y. N. V. Gopal et al. CANCER RESEARCH
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
- (2010) V. E. Kwitkowski et al. ONCOLOGIST
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- (2010) R. B. Corcoran et al. Science Signaling
- An Emerging Role of mTOR in Lipid Biosynthesis
- (2009) Mathieu Laplante et al. CURRENT BIOLOGY
- mTOR and cancer: many loops in one pathway
- (2009) Alejo Efeyan et al. CURRENT OPINION IN CELL BIOLOGY
- mTOR signaling at a glance
- (2009) M. Laplante et al. JOURNAL OF CELL SCIENCE
- Targeting the mTOR Signaling Network for Cancer Therapy
- (2009) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular mechanisms of mTOR-mediated translational control
- (2009) Xiaoju Max Ma et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors
- (2009) T John et al. ONCOGENE
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search